Efficacy of 125I seed implantation combined with intermittent hormonal therapy on moderate- and high-risk non-metastatic prostate cancer.
CONCLUSIONS: IRF-1/PVT1-214 may markedly boost the oxaliplatin-resistance of CRC, resulting in the late TNM stage and poor survival. These findings suggest that the IRF-1/PVT1-214 axis may be a helpful target for intervention in CRC.
PMID: 33455104 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Hormonal Therapy | Hormones | Molecular Biology | Plasmacytoma | Prostate Cancer | Translocation